Ovarian cancer has a poor prognosis even after a complete resection and a platinum adjuvant
chemotherapy because of its high rate of relapses. Clinical research has shown the role of angiogenesis
in the development and progression of ovarian carcinoma. Several factors are involved, specially the
VEGF. Bevacizumab is a humanized anti-VEGF antibody that was approved by the European Medicines
Agency in first line for the treatments of advanced epithelial ovarian cancer, fallopian tube cancer
and primary peritoneal cancer. It has to be combined with carboplatin and paclitaxel followed by maintenance therapy
with bevacizumab alone. Bevacizumab has also been approved by EMA for the treatment of platinum-sensitive ovarian
cancer recurrence in combination with carboplatin and gemcitabine. This literature review aims to provide updates about
angiogenesis in ovarian cancer, pro-and anti-angiogenic factors that regulate angiogenesis, and lists new anti-angiogenic
therapies in different phases of clinical development that aim to improve survival in patients with ovarian cancer.
Keywords: Angiogenesis, anti-angiogenic therapies, bevacizumab, ovarian cancer, VEGF.
Rights & PermissionsPrintExport